Review of evidence that posttransplantation psychiatric treatment commonly affects prolactin levels and thereby influences graft fate

General Hospital Psychiatry

Volumn 28, Issue 3, 2006, Pages 230-233

  Foley, Kevin F ^a   Kast, Richard E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Antipsychotic medicines; Depression; Dopamine; Graft rejection; Prolactin; Psychosis; SSRI; Transplantation

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BROMOCRIPTINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; DROPERIDOL; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; METOCLOPRAMIDE; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERGOLIDE; PERPHENAZINE; PRAMIPEXOLE; PROLACTIN; QUETIAPINE; RISPERIDONE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ZIPRASIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGRANULOCYTOSIS; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CONFUSION; DELIRIUM; DELUSION; DEPRESSION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HALLUCINATION; HUMAN; MENTAL DISEASE; MENTAL HEALTH CARE; NAUSEA; PARANOIA; PARKINSON DISEASE; PROLACTIN BLOOD LEVEL; PSYCHOSIS; THOUGHT DISORDER; TRANSPLANTATION;

ANTIPSYCHOTIC AGENTS; DOPAMINE; GRAFT REJECTION; HUMANS; PROLACTIN; SEROTONIN UPTAKE INHIBITORS; TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; UNITED STATES;

EID: 33646163007     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2006.03.003     Document Type: Article

References (39)

1. Freeman M.E., Kanylcska B., Lerant A., et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev 80 (2000) 1523-1631
2. Montgomery D.W. Prolactin production by immune cells. Lupus 10 (2001) 665-675
3. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation 4 (1997) 171-180
4. 5 dopamine receptors to multiple G proteins: implications for understanding the diversity in receptor-G protein coupling. Mol Neurobiol 16 (1998) 125-134
5. Kast R.E., and Altschuler E.L. Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha. Arch Immunol Ther Exp 53 (2005) 143-147
6. 2 dopamine receptor family; differential coupling to Gi, Gz, and Gs. Cell Mol Neurobiol 19 (1999) 653-664
7. 5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J Neuroimmunol 169 (2005) 161-171
8. 3-dopamine receptors detected in the anterior pituitary. Eur J Pharmacol 71 (1981) 143-146
9. Caron M.C., Beaulieu M., Raymond V., et al. Dopaminergic receptors in the anterior pituitary gland. J Biol Chem 253 (1978) 2244
10. Morikawa K., Oseko F., and Morikawa S. Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 95 3 (1994) 514-518
11. Gerlach M., Double K., Arzberger T., et al. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110 (2003) 1119-1127
12. Kast R.E. TNF has positive and negative self-regulatory feedback cycles centered around cAMP. Int J Immunopharmacol 22 (2000) 1001-1006
13. Hutchinson I.V., Pravica V., Hajeer A., and Sinnott P.J. Identification of high and low responders to allografts. Rev Immunogenet 1 (1999) 323-333
14. Azzawi M., Hasleton P.S., and Hutchinson I.V. TNF-alpha in acute cardiac transplant rejection. Cytokines Cell Mol Ther 5 (1999) 41-49
15. Nagy E., and Berczi I. Hypophysectomized rats depend on residual prolactin for survival. Endocrinology 128 (1991) 2776-2784
16. Kast R.E. Blocking of cyclosporine immunosuppression by neuroleptics. Transplantation 47 (1989) 1095-1096
17. Matera L., Mori M., Geuna M., et al. Prolactin in autoimmunity and antitumor defense. Br J Neuroimmunol 109 (2000) 47-55
18. Richards S.M., and Murphy W.J. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J Neuroimmunol 109 (2000) 56-62
19. Sun R., Gault R.A., Welniak L.A., et al. Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice. Biol Blood Marrow Transplant 9 (2003) 426-434
20. Sun R., Zhang J., Zhang C., Zhang J., Liang S., et al. Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice. Cell Mol Immunol 1 (2004) 129-136
21. Sun R., Wei H., Zhang J., et al. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo. Neuroimmunomodulation 10 (2002-2003) 169-176
22. Woody M.A., Welniak L.A., Richards S., et al. Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation. Neuroimmunomodulation 6 (1999) 69-80
23. Hinterberger-Fischer M., Kier P., Spona J., et al. Prolactin: a possible mediator of graft-versus-host disease following allogeneic bone marrow transplantation in humans. Bone Marrow Transplant 14 (1994) 403-406
24. Hinterberger-Fischer M., and Hinterberger W. Blood stem cell transplantation for breast cancer: new approaches using pre-, peri-, post-transplant immunotherapy. Expert Opin Biol Ther 1 (2001) 1029-1048
25. Hinterberger-Fischer M., Ogris E., Kier P.C., et al. Elevation of plasma prolactin in patients undergoing autologous blood stem-cell transplantation for breast cancer: is its modulation a step toward post-transplant immunotherapy?. Am J Clin Oncol 23 (2000) 325-329
26. Barbee J.G., Conrad E.J., and Jamhour N.J. The effectiveness of olanzapine, risperidone, quetiapine, and ziprazadone as augmentation agents in treatment resistant major depressive disorder. J Clin Psychiatry 65 (2004) 975-981
27. Healy D.L., and Burger H.G. Sustained elevation of serum prolactin by metoclopramide: a clinical model of idiopathic hyperprolactinemia. J Clin Endocrinol Metab 46 (1978) 709-714
28. Daniels G.H., Hayden D.L., Goff D.C., et al. Effect of risperidone dose on serum prolactin level. Endocr Pract 7 (2001) 224
29. Hummer M., and Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 20 (2004) 189-197
30. Goodnick P.J., Rodriguez L., and Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 3 (2002) 1381-1391
31. Cheer S.M., and Wagstaff A.J. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 18 (2004) 173-199
32. Mann K., Rossbach W., Muller M.J., et al. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31 (2006) 256-264
33. Cohrs S., Roher C., Jordan W., et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) 24 (2006) 1-8
34. 2-dopaminergic agonist ropinirol on supine resting and stimulated circulatory and neuroendocrine variables in healthy volunteers. Arzneimittelforschung 40 (1990) 7-13
35. Samuels ER, Hou RH, Langley RW, et al. Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. J Psychopharmacol. [Jan 9; electronic publication ahead of print].
36. Strange P.G. Agonism and inverse agonism at dopamine D2-like receptors. Clin Exp Pharmacol Physiol Suppl 26 (1999) S3-S9
37. Emiliano A.B., and Fudge J.L. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 29 (2004) 833-846
38. Brustolim D, Ribeiro-dos-Santos R, Kast RE, et al. A new chapter in anti-inflammatory treatment opens: the antidepressant bupropion lowers production of TNF-alpha and interferon-gamma in mice. Int Immunopharm 2006 [in press].
39. Kast R.E. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen Hosp Psychiatry 25 (2003) 495-496